Skip to Main Content

Paper Details

Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease.
Am J Gastroenterol
7
2023
Author NameAffiliation
Sengwee TohHarvard Medical School and Harvard Pilgrim Health Care Institute
  • 1 - 1

Datasets

Release 1.2